24
Participants
Start Date
March 31, 2012
Primary Completion Date
May 31, 2012
Study Completion Date
May 31, 2012
GSK1322322 (mesylate salt) Powder for Injection
1500 mg (mesylate salt) as free base, dissolved in sterile water for injection to a concentration of 100 mg/mL free base equivalent and sterilized via filtration. 15 mL of solution, equivalent to 1500 mg GSK 1322322, is the diluted into 0.9% Sodium Chloride Injection prior to infusion
GSK1322322 (freebase) tablets
500 mg tablets for a 1500 mg total single dose (3 tablets). Taken with 240 mL of water
GSK1322322 (mesylate salt) Powder for Oral Solution
1500 mg as a free base, dissolved in purified water to a concentration of 100 mg/mL free base equivalent. 15 mL of solution, equivalent to1500 mg GSK1322322 is administered orally with 225 mL of water
GSK1322322 (freebase) tablets FED
Drug 500 mg tablets for a 1500 mg total single dose (3 tablets) (FED moderate fat meal) Taken with 240 mL of water
GSK Investigational Site, Minneapolis
Lead Sponsor
GlaxoSmithKline
INDUSTRY